A new report by the Global Health Justice Partnership (GHJP), the Treatment Action Group (TAG) and the Initiative for Medicines, Access and Knowledge argues for a global strategy to fight the hepatitis C virus (HCV) that is similar to the HIV/AIDS fight, according to a press release from Yale Law School, which co-hosts GHJP with Yale School of Public Health.
The 51-page report, titled “Ending an Epidemic: Overcoming Barriers to an HCV-Free Future,” warns that global efforts to end the hep C epidemic will not work unless millions of people in low- and middle-income countries are given affordable access to new, highly effective antiviral drugs.
The advocacy groups are pushing for a global strategy similar to ones previously used for improving access to HIV/AIDS treatments. They plan to get cheaper, generic versions of HCV drugs onto international markets by pressuring manufacturers like Gilead Sciences to allow other companies to make them.
Gilead’s hep C drug Sovaldi (sofosbuvir) costs $1,000 a pill or $84,000 for a full course of treatment in the United States. Although Gilead has given out substantial discounts and generic licenses to several low-income nations since releasing Sovaldi in December 2013, the company has not yet been willing to give up control of the hep C market in other countries, including India, where discounted drugs still cost as much as 20 percent of the average annual income.
The report also details several other barriers to hep C treatment, including the high cost of providing specialty HCV care along with the new drugs, as well as the need to improve outreach to key populations at a high risk of infection, such as injection drug users.
“Just like with HIV/AIDS, we’re going to need international donors to step up like they did with the Global Fund to Fight AIDS, Tuberculosis and Malaria, to make HCV treatment a reality for millions around the world,” Karyn Kaplan, the director of international hepatitis and HIV policy and advocacy for TAG, said in the press release.
Hep C affects 185 million people worldwide, which is five times as many people who are living with HIV.
Advertisement
Advocates Adapt Global HIV Strategy for Cheaper HCV Drugs
Advertisement
Advertisement
Comments
Comments